Naltrexone never touches a dopamine receptor, and the MN660 Unit 1 post shows how blocking mu-opioid receptors still dulls the reward a composite drinker gets from alcohol. Searches like "mn 660 unit 1 assignment example", "mn660 unit 1 sample" and "mn660 unit 1 example" land here.
Naltrexone Does Not Block Dopamine: Three Links From the Opioid Receptor to a Drink That No Longer Pays Off
MN660 · Unit 1 Discussion
Posted by [Student Name]
Composite patient written for a model post. No real person is described.
Initial Post
The claim under test: "Naltrexone works by blocking dopamine." The error is in the target. Naltrexone has negligible affinity for dopamine receptors; it is a competitive antagonist at mu-opioid receptors. The shortcut gets one thing right, though: dopamine in the nucleus accumbens does rise less after a drink taken on naltrexone. It gets there by a different route.
The chain runs in three links. First, alcohol releases endogenous opioids such as beta-endorphin. Second, at mu-opioid receptors on GABA interneurons in the ventral tegmental area, those opioids quiet the interneurons, which lifts their inhibitory brake on dopamine neurons. Third, the released dopamine neurons fire more and raise dopamine in the nucleus accumbens, which is felt as reward. Blocking the first receptor in the chain blunts the last step, which is why naltrexone lowers accumbens dopamine without touching a dopamine receptor. Competitive antagonism means the drug occupies the mu receptor without activating it, so the opioids released by drinking find the site already taken.
The composite case shows what that feels like. A 52-year-old man on naltrexone says the second drink "just isn't worth it anymore," and he stops at one most nights. In humans, PET imaging has shown that drinking releases endogenous opioids in the nucleus accumbens and orbitofrontal cortex (Mitchell et al., 2012), and in the COMBINE trial naltrexone improved drinking outcomes when paired with medical management (Anton et al., 2006). One thing the mechanism does not claim: naltrexone does not abolish craving. It blunts the reward of drinking, which is a different thing. A person can still want the first drink strongly; what changes is how rewarding the drinks after it feel, which is why many patients report drinking less rather than stopping.
Reply to a Classmate
Your account of buprenorphine says it "prevents withdrawal and blocks other opioids." Which link did you imply rather than state: its partial agonism, which prevents withdrawal, or its high receptor affinity, which blocks other opioids?
References
Anton, R. F., O'Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., Longabaugh, R., Mason, B. J., Mattson, M. E., Miller, W. R., Pettinati, H. M., Randall, C. L., Swift, R., Weiss, R. D., Williams, L. D., & Zweben, A. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA, 295(17), 2003-2017. https://doi.org/10.1001/jama.295.17.2003
Mitchell, J. M., O'Neil, J. P., Janabi, M., Marks, S. M., Jagust, W. J., & Fields, H. L. (2012). Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Science Translational Medicine, 4(116), 116ra6. https://doi.org/10.1126/scitranslmed.3002902
How this MN660 Unit 1 example is structured
The claim leads, quoted exactly as the prompt gave it. A one-sentence correction follows, locating the drug at the opioid receptor and conceding what the shortcut got right: accumbens dopamine does rise less after a drink taken on naltrexone. The central paragraph is written as a chain in which each sentence answers why the previous one happened, receptor to interneuron to dopamine neuron to accumbens to the felt reward. A brief aside defines competitive antagonism: the drug occupies the receptor without activating it, so opioid released by drinking finds the site already taken. The composite case arrives only after the mechanism, so it illustrates rather than substitutes. The post's last sentence disclaims one thing, that naltrexone abolishes craving. Beneath everything, one classmate is asked which link in their own account was implied rather than stated.
Get an MN660 Unit 1 example written to your instructions
Copy the Unit 1 discussion question from your MN660 section into the request with its rubric, and add the claim or drug it names if that differs from naltrexone. A first post is written free to those instructions and returns in 24-48h, built as a correction that supplies every link between receptor and behavior, then a reply questioning one classmate's unstated step. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN660 Unit 1 questions, answered
Is it acceptable to correct a classmate's mechanism on the board?
Yes, when the correction is specific and courteous. Quote the sentence, say what it gets right, then supply the step it skipped with a source. Instructors in this course generally welcome that exchange, because a mechanism argued in public is closer to what the course trains than a row of agreeing replies. Leave tone and style alone and keep to the pharmacology.
Does the post need a clinical trial, or is a mechanism source enough?
Both usually help. A pharmacology review or text supports the receptor chain, while a trial such as COMBINE shows the chain has a measurable clinical consequence. Posts citing only one side tend to read either as theory with no outcome or as an outcome with no explanation, and the opening board is usually looking for the connection between the two.
Should the post discuss naltrexone dosing or formulations?
No. The board asks why the drug has its effect, not how it is given, and the sample keeps any regimen out of the text entirely. Noting that oral and long-acting injectable forms exist is harmless if the prompt raises it, but amounts, schedules and start criteria belong to the management courses and to the prescriber.